Theranostics 2016; 6(7):918-929. doi:10.7150/thno.14689 This issue


Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform

Andrew B. Satterlee1,2, Leaf Huang1,2✉

1. Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7571, USA;
2. UNC and NCSU Joint Department of Biomedical Engineering, Chapel Hill, NC 27599.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See for full terms and conditions.
Satterlee AB, Huang L. Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform. Theranostics 2016; 6(7):918-929. doi:10.7150/thno.14689. Available from

File import instruction


Graphic abstract

Over the last four years, the Lipid-Calcium-Phosphate (LCP) nanoparticle platform has shown success in a wide range of treatment strategies, recently including theranostics. The high specific drug loading of radiometals into LCP, coupled with its ability to efficiently encapsulate many types of cytotoxic agents, allows a broad range of theranostic applications, many of which are yet unexplored. In addition to providing an overview of current medical imaging modalities, this review highlights the current theranostic applications for LCP using SPECT and PET, and discusses potential future uses of the platform by comparing it with both systemically and locally delivered clinical radiotherapy options as well as introducing its applications as an MRI contrast agent. Strengths and weaknesses of LCP and of nanoparticles in general are discussed, as well as caveats regarding the use of fluorescence to determine the accumulation or biodistribution of a probe.

Keywords: Cancer, Theranostic, SPECT, PET, SIRT, Nanoparticle, LCP.